Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech ...

Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more ...

LONDON (Reuters) -Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its ...

Novo Nordisk stock rose 2.6% after withdrawing from a $10 billion bidding war for Metsera that investors viewed as too ...

The chair and six independent directors of Novo Nordisk are stepping down after a dispute with the Danish drugmaker’s ...

The Novo Nordisk Foundation in Denmark, one of the world’s leading funders of pharmaceutical and biotechnology research, is investing €21.7 million to support emerging and rising Danish researchers in ...

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

The Novo Foundation, through its subsidiary Novo Holdings, owns 25% of the shares and 70% of the votes in Novo Nordisk, making the election of its designees a likely formality when investors gather ...

Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members at ...

But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...

Danish pharmaceutical giant Novo Nordisk said on Tuesday it will hold an extraordinary general meeting on 14 November to ...